These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 12053403)

  • 1. [Drug safety and post-marketing control. Developments since the reform of the 1978 drug regulation].
    Wille H; Schönhöfer PS
    Internist (Berl); 2002 Apr; 43(4):469-70, 473-81. PubMed ID: 12053403
    [No Abstract]   [Full Text] [Related]  

  • 2. [The Therapeutic Drug Committee of German Physicians. 50 years in the service of drug safety in Germany].
    Müller-Oerlinghausen B; Tiaden JD
    Internist (Berl); 2002 Apr; 43(4):482, 485-92. PubMed ID: 12053404
    [No Abstract]   [Full Text] [Related]  

  • 3. [New institute for additional drug evaluation. Do we really need another barrier?].
    Schmidt K
    MMW Fortschr Med; 2003 Jul; 145(29-30):55-6. PubMed ID: 12958781
    [No Abstract]   [Full Text] [Related]  

  • 4. Drug safety reform at the FDA--pendulum swing or systematic improvement?
    McClellan M
    N Engl J Med; 2007 Apr; 356(17):1700-2. PubMed ID: 17435081
    [No Abstract]   [Full Text] [Related]  

  • 5. FDA attempting to overcome major roadblocks in monitoring drug safety.
    Zielinski SL
    J Natl Cancer Inst; 2005 Jun; 97(12):872-3. PubMed ID: 15956645
    [No Abstract]   [Full Text] [Related]  

  • 6. [European drug agency and drug management].
    Barfuss W
    Leber Magen Darm; 1996 Jul; 26(4):191-2. PubMed ID: 8965600
    [No Abstract]   [Full Text] [Related]  

  • 7. Regulatory experts debate FDA's authority.
    Young D
    Am J Health Syst Pharm; 2007 May; 64(9):910, 912. PubMed ID: 17468140
    [No Abstract]   [Full Text] [Related]  

  • 8. [Patient-relevant outcomes and surrogates in the early benefit assessment of drugs: first experiences].
    Kvitkina T; ten Haaf A; Reken S; McGauran N; Wieseler B
    Z Evid Fortbild Qual Gesundhwes; 2014; 108(8-9):528-38. PubMed ID: 25523852
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Reform of drug regulation--beyond an independent drug-safety board.
    Ray WA; Stein CM
    N Engl J Med; 2006 Jan; 354(2):194-201. PubMed ID: 16407517
    [No Abstract]   [Full Text] [Related]  

  • 10. The impact of FDA reform.
    Trunzo J
    Med Device Technol; 2003 Apr; 14(3):36-7. PubMed ID: 12789699
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Effect of the German Act on the reform of the market for medicinal products (AMNOG) on the quality of neurological and psychiatric treatment].
    Hamer H; Meyer-Lindenberg A
    Nervenarzt; 2016 Apr; 87(4):351-2. PubMed ID: 27025218
    [No Abstract]   [Full Text] [Related]  

  • 12. [The safety and registration of pharmaceuticals from the point of view of the medical practitioner].
    Kaiser RH
    Radiologe; 2002 Dec; 42(12):1016-24; quiz 1024-5. PubMed ID: 12602329
    [No Abstract]   [Full Text] [Related]  

  • 13. [How AMOG limits the supply of diabetes drugs].
    Oberhofer E
    MMW Fortschr Med; 2015 Aug; 157(14):24. PubMed ID: 26289868
    [No Abstract]   [Full Text] [Related]  

  • 14. The role of the pharmaceutical industry in disseminating pharmacovigilance practice in developing countries.
    Shani S; Yahalom Z
    Food Drug Law J; 2008; 63(3):701-11. PubMed ID: 19031669
    [No Abstract]   [Full Text] [Related]  

  • 15. [Negative would be welcome. The question is whose brain child this is].
    Hakimi R
    MMW Fortschr Med; 2006 Nov; 148(44):8. PubMed ID: 17632867
    [No Abstract]   [Full Text] [Related]  

  • 16. [Earlier value assessment of pharmaceutical products and medical science].
    Selbmann HK
    Nervenarzt; 2016 Apr; 87(4):353-5. PubMed ID: 27000270
    [No Abstract]   [Full Text] [Related]  

  • 17. Contribution of industry funded post-marketing studies to drug safety: survey of notifications submitted to regulatory agencies.
    Spelsberg A; Prugger C; Doshi P; Ostrowski K; Witte T; Hüsgen D; Keil U;
    BMJ; 2017 Feb; 356():j337. PubMed ID: 28174182
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Two UK Government proposals bearing on drug safety.
    Griffin JP
    Adverse Drug React Toxicol Rev; 1997 Mar; 16(1):1-7. PubMed ID: 9192053
    [No Abstract]   [Full Text] [Related]  

  • 19. Electronic Reporting for Clinical Drug Safety and Pharmacovigilance. 29 - 30 October 2002, Amsterdam, The Netherlands.
    Hennig R
    Expert Opin Drug Saf; 2003 Mar; 2(2):195-7. PubMed ID: 12904118
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A primer of drug safety surveillance: an industry perspective. Part I: Information flow, new drug development, and federal regulations.
    Allan MC
    J Pharm Technol; 1992; 8(4):162-7. PubMed ID: 10121011
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.